TY - JOUR
T1 - Outcome Measures in Large Vessel Vasculitis
T2 - Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments
AU - Rimland, Casey A.
AU - Quinn, Kaitlin A.
AU - Rosenblum, Joel S.
AU - Schwartz, Mollie N.
AU - Bates Gribbons, K.
AU - Novakovich, Elaine
AU - Sreih, Antoine G.
AU - Merkel, Peter A.
AU - Ahlman, Mark A.
AU - Grayson, Peter C.
N1 - Publisher Copyright:
© 2019, American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Objective: To assess the relationship between measures of disease assessment in patients with large vessel vasculitis. Methods: Patients with giant cell arteritis (GCA) or Takayasu arteritis (TAK) were recruited into a prospective, observational cohort. Assessments within the following outcomes were independently recorded: 1) patient-reported outcomes (Multidimensional Fatigue Inventory, patient global assessment of disease activity [PtGA], Short Form 36 health survey [SF-36], Brief Illness Perception Questionnaire), 2) physician global assessment of disease activity (PhGA), 3) laboratory outcomes (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR]), and 4) imaging outcomes (PETVAS, a qualitative score of vascular 18F-fluorodeoxyglucose–positron emission tomography activity). Results: Analyses were performed on 112 patients (GCA = 56, TAK = 56), over 296 visits, with a median follow-up of 6 months. Correlation network analysis revealed assessment measures clustered independently by type of outcome. PhGA was centrally linked to all other outcome types, but correlations were modest (ρ = 0.12–0.32; P < 0.05). PETVAS, CRP level, and PtGA were independently associated with clinically active disease. All 4 patient-reported outcomes strongly correlated with each other (ρ = 0.35–0.60; P < 0.0001). Patient-reported outcomes were not correlated with PETVAS, and only PtGA correlated with CRP level (ρ = 0.16; P < 0.01). Patients whose clinical assessment changed from active disease to remission (n = 29) had a corresponding significant decrease in ESR, CRP level, and PETVAS at the remission visit. Patients whose clinical assessment changed from remission to active disease (n = 11) had a corresponding significant increase in CRP level and PtGA at the active visit. Conclusion: Measures of disease assessment in large vessel vasculitis consist of independent, yet complementary, outcomes, supporting the need to develop composite outcome measures or a standard set of measures covering multiple types of outcomes.
AB - Objective: To assess the relationship between measures of disease assessment in patients with large vessel vasculitis. Methods: Patients with giant cell arteritis (GCA) or Takayasu arteritis (TAK) were recruited into a prospective, observational cohort. Assessments within the following outcomes were independently recorded: 1) patient-reported outcomes (Multidimensional Fatigue Inventory, patient global assessment of disease activity [PtGA], Short Form 36 health survey [SF-36], Brief Illness Perception Questionnaire), 2) physician global assessment of disease activity (PhGA), 3) laboratory outcomes (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR]), and 4) imaging outcomes (PETVAS, a qualitative score of vascular 18F-fluorodeoxyglucose–positron emission tomography activity). Results: Analyses were performed on 112 patients (GCA = 56, TAK = 56), over 296 visits, with a median follow-up of 6 months. Correlation network analysis revealed assessment measures clustered independently by type of outcome. PhGA was centrally linked to all other outcome types, but correlations were modest (ρ = 0.12–0.32; P < 0.05). PETVAS, CRP level, and PtGA were independently associated with clinically active disease. All 4 patient-reported outcomes strongly correlated with each other (ρ = 0.35–0.60; P < 0.0001). Patient-reported outcomes were not correlated with PETVAS, and only PtGA correlated with CRP level (ρ = 0.16; P < 0.01). Patients whose clinical assessment changed from active disease to remission (n = 29) had a corresponding significant decrease in ESR, CRP level, and PETVAS at the remission visit. Patients whose clinical assessment changed from remission to active disease (n = 11) had a corresponding significant increase in CRP level and PtGA at the active visit. Conclusion: Measures of disease assessment in large vessel vasculitis consist of independent, yet complementary, outcomes, supporting the need to develop composite outcome measures or a standard set of measures covering multiple types of outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85089966490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089966490&partnerID=8YFLogxK
U2 - 10.1002/acr.24117
DO - 10.1002/acr.24117
M3 - Article
C2 - 31785185
AN - SCOPUS:85089966490
SN - 2151-464X
VL - 72
SP - 1296
EP - 1304
JO - Arthritis Care and Research
JF - Arthritis Care and Research
IS - 9
ER -